PRME

Prime Medicine, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1894562Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$5.0M

Net Income FY2025

$(201.0M)

EPS (Basic, as reported)

$-1.35

Net Margin FY2025

-4342.4%

ROE FY2025

-166.4%

Total Equity

$121.0M

Shares Out

181M

Business description

Prime Medicine, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 5 → 5 +0% CAGR

Fiscal yearFY2020⚑FY2021⚑FY2022⚑FY2023FY2024FY2025

Revenue500035

Research & development(3)(71)(87)(148)(155)(161)

General & administrative(3)(14)(30)(43)(50)(52)

Total operating expenses(6)(84)(117)(205)(205)(213)

Operating income(1)(84)(117)(205)(202)(208)

Interest & investment income———344

Other income (expense), net(1)(81)(6)677

Income tax expense(2)0(1)000

Net income(3)(165)(122)(198)(196)(201)

EPS — basic($1.91)($14.19)($4.19)($2.18)($1.65)($1.35)

EPS — diluted($1.91)($14.19)($4.19)($2.18)($1.65)($1.35)

Shares outstanding — basic (M)3133491119149

Shares outstanding — diluted (M)3133491119149

⚑ Weighted-average shares changed ×4.33 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×2.62 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×2.68 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.